Dopal
Dopal is a metabolite and aldehyde neurotoxin of Dopamine (HY-B0451). Dopal exhibits cytotoxicity, induces α-synuclein oligomerization and aggregation, and is closely associated with the pathogenesis of Parkinson's disease. Dopal can be used in research related to Parkinson's disease.
For research use only. We do not sell to patients.
- Purity: 90.0%
- CAS No.: 5707-55-1
- Formula: C8H8O3
- Molecular Weight:152.15
-
Storage:
-80°C
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All α-synuclein Isoforms
More
Biological Activity
|
α-synuclein Aggregation |
Dopal (1.5-1500 μM; 0-4 h) induces dose- and time-dependent aggregation of purified human recombinant α-synuclein in a cell-free system; aggregation initiates at concentrations as low as 1.5 μM, and large polymeric α-synuclein aggregates form at concentrations of 300 μM and above[1].
Dopal (3 μM-1 mM; 2-8 h) induces dose-dependent α-synuclein aggregation and cytotoxicity in SHSY-5Y cells overexpressing wild-type α-synuclein, with significant aggregation observed at concentrations ≥30 μM, oligomer formation initiated at 3 μM, and rapid cell death occurring at 1 mM[1].
Dopal (100-150 μM; 18-24 h) exhibits toxicity to SH-SY5Y cells and also induces cell apoptosis[2].
Dopal (100-200 μM; 16-24 h) induces the formation of α-synuclein-EGFP dimers in SH-SY5Y cells overexpressing α-synuclein-EGFP[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SH-SY5Y neuroblastoma cells
-
Concentration:100 μM
-
Incubation Time:24 h
-
Result:Induced ~30% death in the SH-SY5Y cell population, significantly reducing cell viability compared to untreated controls.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, 2-month-old, 300 g, unilateral stereotactic injection into substantia nigra)[1]
-
Dosage:1.0 μg; 0.2 μg
-
Administration:stereotactic injection into substantia nigra; single dose
-
Result:Increased 50 to 170 kDa α-synuclein (AS) oligomers by 2.75-fold relative to vehicle control, with these oligomers accounting for 63% of total AS at 4 hours post-injection with 1.0 μg dose.
Induced a lesser increase in 50 to 170 kDa AS oligomers at 4 hours post-injection with 0.2 μg dose compared to 1.0 μg dose.
Caused loss of tyrosine hydroxylase immunoreactivity in the substantia nigra at 24 and 48 hours post-injection with both 1.0 μg and 0.2 μg doses. Failed to detect large AS aggregates via immunohistochemistry at 4, 24, or 48 hours post-injection.
Chemical Information
-
CAS No. 5707-55-1
-
Appearance Liquid
-
Molecular Weight 152.15
-
Formula C8H8O3
-
Color Colorless to light yellow
-
SMILES
O=CCC1=CC=C(O)C(O)=C1
-
Shipping
Shipping with dry ice.
-
Storage
-80°C
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Burke WJ, et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 2008;115(2):193-203. [Content Brief]
[2]. Bloch DN, et al. Scavenging neurotoxic aldehydes using lysine carbon dots. Nanoscale Adv. 2023;5(5):1356-1367. Published 2023 Jan 19. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Dopal Related Classifications
HY-121252 Related Classifications
Powered by Bioz